JP2016513665A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513665A5 JP2016513665A5 JP2016502251A JP2016502251A JP2016513665A5 JP 2016513665 A5 JP2016513665 A5 JP 2016513665A5 JP 2016502251 A JP2016502251 A JP 2016502251A JP 2016502251 A JP2016502251 A JP 2016502251A JP 2016513665 A5 JP2016513665 A5 JP 2016513665A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- laquinimod
- transdermal patch
- patch according
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 229960004577 laquinimod Drugs 0.000 claims description 35
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims description 34
- 239000003623 enhancer Substances 0.000 claims description 13
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 230000035515 penetration Effects 0.000 claims description 8
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 8
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 6
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 239000003961 penetration enhancing agent Substances 0.000 claims description 4
- -1 polyethylene terephthalate Polymers 0.000 claims description 4
- 150000003505 terpenes Chemical class 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229940087168 alpha tocopherol Drugs 0.000 claims description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000004446 fluoropolymer coating Substances 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- NUKZAGXMHTUAFE-UHFFFAOYSA-N hexanoic acid methyl ester Natural products CCCCCC(=O)OC NUKZAGXMHTUAFE-UHFFFAOYSA-N 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 2
- 150000003462 sulfoxides Chemical class 0.000 claims description 2
- 235000007586 terpenes Nutrition 0.000 claims description 2
- 229960000984 tocofersolan Drugs 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002076 α-tocopherol Substances 0.000 claims description 2
- 235000004835 α-tocopherol Nutrition 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361781585P | 2013-03-14 | 2013-03-14 | |
| US61/781,585 | 2013-03-14 | ||
| PCT/US2014/026807 WO2014152009A1 (en) | 2013-03-14 | 2014-03-13 | Transdermal formulations of laquinimod |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016513665A JP2016513665A (ja) | 2016-05-16 |
| JP2016513665A5 true JP2016513665A5 (enExample) | 2017-05-18 |
Family
ID=50729775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502251A Withdrawn JP2016513665A (ja) | 2013-03-14 | 2014-03-13 | ラキニモドの経皮製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160038435A1 (enExample) |
| EP (1) | EP2968203A1 (enExample) |
| JP (1) | JP2016513665A (enExample) |
| CA (1) | CA2900977A1 (enExample) |
| HK (1) | HK1220125A1 (enExample) |
| IL (1) | IL240557A0 (enExample) |
| MX (1) | MX2015010967A (enExample) |
| WO (1) | WO2014152009A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| WO2015138887A1 (en) * | 2014-03-14 | 2015-09-17 | Teva Pharmaceutical Industries Ltd. | Transmucosal delivery of laquinimod by oral patches |
| CN112656778A (zh) * | 2020-12-28 | 2021-04-16 | 广东红珊瑚药业有限公司 | 一种压敏胶基质以及一种贴剂 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| US20040033253A1 (en) * | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| RS53666B1 (sr) | 2005-10-19 | 2015-04-30 | Teva Pharmaceutical Industries Ltd | Kristali lakvinimod natrijuma i proces za njihovo dobijanje |
| UA96449C2 (en) | 2006-06-12 | 2011-11-10 | Тева Фармасьютикл Индастриз, Лтд. | Stable laquinimod preparations |
| SI2234485T1 (sl) | 2007-12-20 | 2014-03-31 | Teva Pharmaceutical Industries Ltd. | Stabilni lakvinimodni pripravki |
| BRPI0913518A2 (pt) | 2008-09-03 | 2016-07-26 | Teva Pharma | composto, composição farmacêutica, e, método de tratamento de um distúrbio mediado por função imune |
| WO2010147665A1 (en) | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| CA2769623A1 (en) | 2009-07-30 | 2011-02-03 | Teva Pharmaceutical Industries Ltd. | Treatment of crohn's disease with laquinimod |
| HUE029983T2 (en) | 2009-08-10 | 2017-04-28 | Teva Pharma | Treatment of BDNF-related diseases with laquinimod |
| DE102010026879A1 (de) * | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
| CN102781240A (zh) | 2010-03-03 | 2012-11-14 | 泰华制药工业有限公司 | 用拉喹莫德和甲氨蝶呤的组合治疗类风湿性关节炎 |
| BR112012022064A2 (pt) | 2010-03-03 | 2015-09-08 | Teva Pharma | tratamento de artrite lúpica usando laquinimod |
| BR112012021905A2 (pt) | 2010-03-03 | 2015-09-29 | Teva Pharma | tratamento de nefrite lúpica usando laquinimod |
| US8252993B1 (en) | 2010-05-25 | 2012-08-28 | Pioneer Hi-Bred International, Inc. | Inbred maize variety PH18FN |
| MX2013000333A (es) | 2010-07-09 | 2013-02-26 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma. |
| BR112013000607A2 (pt) | 2010-07-09 | 2016-06-28 | Teva Pharma | 5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-di-hidroquinolina-3-carboxamida, os sais e suas utilizações |
| KR20130124518A (ko) | 2010-12-07 | 2013-11-14 | 테바 파마슈티컬 인더스트리즈 리미티드 | 다발경화증 환자의 피로를 감소시키고, 기능 상태를 개선시키고, 삶의 질을 개선시키기 위한 라퀴니모드의 용도 |
-
2014
- 2014-03-13 WO PCT/US2014/026807 patent/WO2014152009A1/en not_active Ceased
- 2014-03-13 CA CA2900977A patent/CA2900977A1/en not_active Abandoned
- 2014-03-13 JP JP2016502251A patent/JP2016513665A/ja not_active Withdrawn
- 2014-03-13 EP EP14724199.6A patent/EP2968203A1/en not_active Withdrawn
- 2014-03-13 US US14/773,658 patent/US20160038435A1/en not_active Abandoned
- 2014-03-13 HK HK16108223.4A patent/HK1220125A1/zh unknown
- 2014-03-13 MX MX2015010967A patent/MX2015010967A/es unknown
-
2015
- 2015-08-13 IL IL240557A patent/IL240557A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5542665B2 (ja) | マトリックス型経皮投与剤およびその製造方法 | |
| JP5073124B2 (ja) | ノルアドレナリン作動性・特異的セロトニン作動性抗うつ薬含有経皮吸収型貼付製剤 | |
| TWI542368B (zh) | 含有血清素受體拮抗劑之貼劑 | |
| CN1450882A (zh) | 石杉碱经皮给药制剂 | |
| WO2009017767A2 (en) | Compositions and methods for dermally treating neuropathy with minoxidil | |
| JP2016520638A5 (enExample) | ||
| JPWO2007142295A1 (ja) | 新規テープ製剤 | |
| CN103432104B (zh) | 一种含有普拉克索的透皮贴剂 | |
| TWI687239B (zh) | 貼附劑 | |
| CN107427472B (zh) | 贴附剂 | |
| RU2004131866A (ru) | Форма для трансэпикутального введения для лечения синдрома усталых ног | |
| JP2016513665A5 (enExample) | ||
| JP2011507904A (ja) | アルプラゾラムおよび他の薬物を経皮送達するためのパッチ、製剤および関連する方法 | |
| CN110022864B (zh) | 用于治疗睡眠障碍的经皮吸收制剂 | |
| CN107484412B (zh) | 含有罗匹尼罗的贴剂 | |
| CN102970974B (zh) | 用于治疗皮炎和牛皮癣的去炎松缩酮制剂 | |
| JP2001058961A (ja) | 経皮吸収促進剤及び経皮吸収型製剤 | |
| JP2018535225A (ja) | 経皮薬剤送達のためのシステムおよび方法 | |
| JP2017190309A (ja) | リバスチグミン経皮吸収製剤 | |
| CN116712413A (zh) | 一种普拉克索透皮贴剂 | |
| JP2018104418A (ja) | 鎮痒剤を含有するロチゴチン経皮吸収型貼付製剤 | |
| JPH03112927A (ja) | 経皮吸収貼付剤 | |
| JP2017226618A (ja) | リュープロレリンの経皮吸収型製剤 | |
| JP2014122206A (ja) | 経皮吸収型製剤 | |
| JP2013075866A (ja) | 乾癬治療用テープ剤 |